Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
The company received gross proceeds of approximately US$1.7 million and net proceeds,
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Development services for gene and cell therapies is planned to begin first in 2025
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Subscribe To Our Newsletter & Stay Updated